Pfizer Inc banner

Pfizer Inc
XETRA:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
XETRA:PFE
Watchlist
Price: 22.8 EUR 1.15% Market Closed
Market Cap: €129.7B

P/FCFE

24.3
Current
107%
More Expensive
vs 3-y average of 11.7

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
24.3
=
Market Cap
€153.8B
/
Free Cash Flow to Equity
$6.2B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
24.3
=
Market Cap
€153.8B
/
Free Cash Flow to Equity
$6.2B

Valuation Scenarios

Pfizer Inc is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (11.7), the stock would be worth €10.99 (52% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-61%
Maximum Upside
No Upside Scenarios
Average Downside
37%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 24.3 €22.8
0%
3-Year Average 11.7 €10.99
-52%
5-Year Average 9.6 €8.99
-61%
Industry Average 18.2 €17.09
-25%
Country Average 21.9 €20.53
-10%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
US
Pfizer Inc
XETRA:PFE
149.7B EUR 24.3 19.3
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9
FR
Sanofi SA
PAR:SAN
96.5B EUR 9 10.2
P/E Multiple
Earnings Growth PEG
US
Pfizer Inc
XETRA:PFE
Average P/E: 472
19.3
22%
0.9
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7
FR
Sanofi SA
PAR:SAN
10.2
16%
0.6

Market Distribution

In line with most companies in the United States of America
Percentile
48th
Based on 7 576 companies
48th percentile
21
Low
0 — 13.1
Typical Range
13.1 — 36.5
High
36.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.1
Median 21.9
70th Percentile 36.5
Max 3 188 432.5

Pfizer Inc
Glance View

Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.

PFE Intrinsic Value
28.01 EUR
Undervaluation 19%
Intrinsic Value
Price €22.8
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett